Why the study?
HFpEF is increasing in incidence with no effective treatment available due to its complex pathophysiology and clinical heterogeneity, warranting an overview of transcriptomic biomarker research.
Transcriptomic biomarker research in HFpEF holds potential for advancing early diagnosis, prognostication, and the development of tailored therapies for a highly heterogeneous patient population.
Transcriptomic insights in HFpEF remain investigational; leaves open improved diagnosis and therapies pending prospective validation.
Heart failure with preserved ejection fraction (HFpEF) is increasing in incidence and has a higher prevalence compared with heart failure with reduced ejection fraction. So far, no effective treatment of HFpEF is available, due to its complex underlying pathophysiology and clinical heterogeneity. This article aims to provide an overview and a future perspective of transcriptomic biomarker research in HFpEF. Detailed characterisation of the HFpEF phenotype and its underlying molecular pathomechanisms may open new perspectives regarding early diagnosis, improved prognostication, new therapeutic targets and tailored therapies accounting for patient heterogeneity, which may improve quality of life. A combination of cross-sectional and longitudinal study designs with sufficiently large sample sizes are required to support this concept.
No takes yet. Share an insight, caveat, or question.
Rosch et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: